• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.13% Nasdaq Up0.14%

    More On SKP.L



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Skyepharma PLC (SKP.L)

    460.25 Down 3.50(0.75%) 5:59AM EDT
    ProfileGet Profile for:
    Skyepharma PLC
    46-48 Grosvenor Gardens
    London, SW1W 0EB
    United Kingdom - Map
    Phone: 44 20 7881 0524
    Fax: 44 20 7881 1199
    Website: http://www.skyepharma.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Major
    Full Time Employees:108

    Business Summary 

    Skyepharma PLC develops and sells oral and inhalation pharmaceutical products worldwide. The company’s inhalation products include flutiform, an inhalation drug for asthma; and Relvar Ellipta/Breo Ellipta, Anoro Ellipta, and Incruse Ellipta, which are used for the treatment of asthma and chronic obstructive pulmonary diseases. It also offers Solaraze, a topical gel treatment for actinic keratosis; and Exparel, a bupivacaine injectable product for post-surgical pain management. The company’s oral drug delivery products comprise RAYOS/Lodotra for the treatment of morning stiffness associated with rheumatoid arthritis; Requip, which provides smoother delivery of ropinirole; Xatra/Uroxatral, an alpha blocker product; Madopar DR/ Prolopa, an oral treatment for Parkinson’s disease; Sular, a calcium channel blocker antihypertensive agent; and ZYFLO CR, an extended-release formulation of the oral asthma drug zileuton. Its oral drug delivery products also comprise Paxil CR, an anti-depressant; Diclofenacratiopharm Uno, a dual release diclofenac sodium formulation for pain/inflammation; Triglide, an oral treatment for elevated blood lipid disorders; and Coruno for the oral treatment of chronic angina pectoris. The company has partnership agreements with various companies, including Sanofi, Mundipharma, and Kyorin. Skyepharma PLC was founded in 1910 and is headquartered in London, the United Kingdom.

    Key Statistics

    Company Websites 
    Home Page
    Investor Relations
    Search Yahoo! for:
    More on Skyepharma PLC

    Key Executives 
    Mr. Peter William Grant , 60
    Chief Exec. Officer and Exec. Director
    Mr. Andrew Derodra , 50
    Chief Financial Officer and Exec. Director
    Mr. John Murphy , 63
    Gen. Counsel and Company Sec.
    Mr. Christian Pangratz ,
    Exec. VP of Bus. Devel. and Alliance Management
    Dr. Geraldine Venthoye ,
    Exec. VP of Pharmaceutical Devel.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in GBp.